LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer Authors: Liguang Wang, Xue Chen, Xiaojiao Li, Yu Wang, Rong Shen Published: 2026 ABSTRACT AbstractAimEverolimus is approved for hormone receptor-positive, HER2-negative breast cancer, but resistance mechanisms remain incompletely understood. This study aimed to investigate the functional role of LRRC32 in mediating Everolimus resistance using patient-derived organoid (PDO) models of this breast cancer subtype.Materials and MethodsEverolimus-resistant and sensitive breast cancer organoids were established from patient-derived tumor tissues. RNA sequencing was performed to compare expression profiles. In vitro functional assays were conducted, including LRRC32 overexpression and shRNA-mediated knockdown, MTT cell viability assay, flow cytometric apoptosis detection, and flow cytometric cell cycle analysis.ResultsRNA sequencing identified significant LRRC32 upregulation in resistant cells with a fold change of 180.46 (p < 0.001). LRRC32 overexpression reduced apoptosis and enhanced cell survival, whereas knockdown increased apoptosis. Cell cycle analysis showed that LRRC32 knockdown in resistant cells significantly increased the G1-phase fraction, hindering G0/G1-to-S transition.ConclusionOur findings suggest that LRRC32 plays a pivotal role in modulating the sensitivity of breast cancer cells to Everolimus.Keywords: everolimus, breast cancer, drug resistance, organoids, LRRC32 Introduction Breast cancer is the most common cancer in women globally and the leading cause of cancer-related deaths among them.1 The main treatment options include surgery, radiation therapy, chemotherapy, endocrine therapy, and molecularly targeted therapy. The specific regimen is determined based on the patient’s clinical profile, including tumour size, location, pathological type, hormone receptor status, and HER-2 status. Long-term estrogen exposure is a key carcinogenic driver in breast carcinogenesis.2 Over 70% of patients are hormone receptor-positive (estrogen and/or progesterone receptors).3 Consequently, endocrine therapy represents the primary treatment for breast cancer.4 Standard regimens include the estrogen receptor antagonist tamoxifen and aromatase inhibitors (AIs; eg, letrozole) that suppress extragonadal estrogen synthesis.5 However, resistance to endocrine therapy is commonly acquired during treatment, limiting long-term efficacy. The genomic landscape of endocrine-resistant breast cancer has been extensively characterized by large-scale sequencing efforts. Razavi et al prospectively sequenced 1501 hormone receptor-positive breast cancers and identified three major, mutually exclusive classes of genomic alterations driving endocrine resistance: ESR1 hotspot mutations, activating MAPK pathway alterations in ERBB2, NF1, KRAS and other effectors, and alterations in ER transcriptional regulators such as FOXA1, CTCF and MYC. Notably, the PI3K/AKT/mTOR pathway is also frequently dysregulated in this subtype, with PIK3CA mutations identified in approximately 36% of HR⁺ breast cancers in the same cohort.6 Endocrine resistance in breast cancer is well-documented and frequently involves PI3K/AKT/mTOR pathway dysregulation.7,8 Activation of mTOR, a downstream effector of PI3K/AKT signaling, promotes protein synthesis, suppresses apoptosis, and enhances cancer cell survival.9 Although the mTOR inhibitor Everolimus has been approved for HR⁺/HER2− breast cancer in combination with endocrine therapy, its clinical efficacy remains limited due to diverse resistance mechanisms, including adaptive feedback activation of PI3K/AKT, compensatory MAPK pathway upregulation, and acquired mTOR mutations.10,11 The full spectrum of mechanisms underlying Everolimus resistance remains incompletely characterized, prompting the present investigation to identify novel mediators such as LRRC32. We focused on LRRC32 because it was the most significantly upregulated gene in Everolimus-resistant organoids. LRRC32 encodes GARP, a cell-surface docking receptor for latent TGF-β that promotes immune tolerance and tumor progression. Importantly, the LRRC32 locus lies within chromosome 11q13, a region frequently amplified in breast cancer, and its amplification has been linked to hormone resistance in prostate cancer, suggesting a potential role in therapy resistance. However, whether LRRC32 modulates sensitivity to mTOR inhibition in breast cancer remains unknown, prompting our investigation into its functional role in Everolimus resistance. To address this question, we employed patient-derived organoids (PDOs) as a physiologically relevant model system. While traditional cell lines have limitations in recapitulating human tumor pathophysiology, PDOs retain the histological and genetic heterogeneity of the parental tumors and offer a more clinically translatable platform for studying therapy resistance. Here, we used PDOs to characterize the role of LRRC32 in Everolimus resistance and to explore its potential as a therapeutic target in hormone receptor-positive, HER2-negative breast cancer. Materials and Methods Patients A total of 30 patients with recurrent or advanced breast cancer, diagnosed as hormone receptor-positive and HER-2 negative, were enrolled. Fresh tumor tissue samples were obtained through biopsy and sent to the laboratory for culture before chemotherapy or endocrine therapy, which was administered according to NCCN clinical guidelines. A drug sensitivity test was conducted simultaneously in the laboratory. The IC50 was calculated using five different drug concentrations to determine sensitivity. Drug sensitivity classification is established based on the ratio of IC50 to clinical peak plasma concentration (Cmax): Highly sensitive (IC50≤0.1×Cmax): Drug significantly inhibits organoid viability at concentrations below 10% of therapeutic levels, predicting potential high clinical efficacy. Moderately sensitive (0.1×Cmax5×Cmax): Organoids show no response at concentrations exceeding 5× maximum tolerated concentration, indicating clinical treatment failure. Meanwhile, clinical efficacy was observed and compared to verify whether the drug sensitivity results were consistent with those of the cultured organoid cells. The drugs used for susceptibility testing were all approved for use in China and were produced by the same manufacturer as those in the clinical group. Integrated Assessment Criteria Combining In Vitro and Clinical Evaluations as follows. Drug-sensitive in vitro models: Strong sensitivity + Moderate sensitivity; Drug-resistant in vitro models: Mild sensitivity + Resistance; Clinical response rate (RR): RR (%) = (Number of Complete Response + Partial Response cases) / Total evaluable cases × 100%; Clinical non-response rate: Non-response rate (%) = (Number of Stable Disease + Progressive Disease cases) / Total evaluable cases × 100%. Based on the validation of clinical drug sensitivity and clinical evaluations, a total of 10 patients with estrogen receptor-positive and HER-2 negative status who responded well to Everolimus were selected. Organoids from these cases were cultured in the presence of gradually increasing concentrations of Everolimus until resistance was achieved. RNA from tumor organoid cells, before and after the development of drug resistance, was extracted, and RNA sequencing was performed to compare the signaling pathways and RNA characteristics. Organoid Preparation and Cell Transfection Fresh tumor samples (surgically resected or biopsy samples) were cut into pieces with 1–3 cubic millimeters. Part of the sample was sent for pathological examination, another part was frozen, and the remaining tissue was used for organoid culture (>5x5x5 mm). The remaining tissue was further chopped and then digested into single cells using collagenase. After counting the cells, they were suspended in cold BME and plated in 24-well cell culture dishes. A growth medium containing the necessary growth factors for breast cancer cell growth was then added. The medium was changed every 4 days, and the cells were monitored for growth. When they reached a certain confluence, they were subcultured at a ratio of 1:4. The cells were either cryopreserved or used for experimental research. Resistant organoids were established by culturing sensitive organoids in gradually increasing concentrations of Everolimus (starting from the initial IC50, up to 10 µM) over 6–8 passages. Stable knockdown of LRRC32 in the breast cancer organoid cells was performed using short hairpin RNA (shRNA)(GenePharma, Shanghai, China) according to the manufacturer’s protocol. The target sequence for shRNA-LRRC32 and a nonspecific control sequence were inserted into the shRNA vector before proceeding with transfection. All groups were performed in triplicate. Paraffin Embedding and H&E Staining For paraffin embedding, tumor cells were collected and resuspended in OrganoPro breast cancer organoid medium (K2 ONCOLOGY, Beijing, China). Precooled diluted matrix gel (Corning, Newyork, USA) was added, and after thorough mixing, 200 µL of the mixture was added to each well of a 24-well cell culture dish. The plate was incubated at 37°C for 30 mins, followed by the addition of 400 µL of OrganoPro breast cancer organoid medium. Culturing continued for 1 week, with the medium replaced every 3 days until the tumor organoids reached a stage suitable for passaging. The matrix gel was then dissolved at 4°C for use. The cultured tumor organoids were collected using a Pasteur pipette, and TrypLE (Thermo Fisher Scientific, Massachusetts, USA) was added to digest the organoids, forming a single-cell suspension. After cell counting, cell concentration was adjusted to 1×106 cells/mL using OrganoPro breast cancer organoid medium and then resuspended with 2.4 mL. The matrix gel mixture was prepared and kept on ice. The cell suspension and matrix gel were mixed, and 200 µL of the mixture was added into each hole of a 24-well plate for a total of 12 wells. The plate was incubated at 37°C for 30 mins and supplemented with 400 µL solution. Culturing continued for 48–72 h. The cells were then centrifuged, and the resulting cell pellets were collected and fixed with 1 mL of 4% PFA for subsequent paraffin embedding and section H&E staining. RNA Sequencing The tumor organoids were cultured for 14 days. Prior to trypsin digestion, the organoids were subjected to: (1) 45-minute incubation on ice to dissociate the Matrigel (Corning, Newyork, USA), (2) three washes with DPBS (Dulbecco’s Phosphate-Buffered Saline), (3) mechanical disruption via needle shearing, (4) homogenization using QIAshredder columns (Qiagen, German), and (5) DNase treatment. The cultured cells were then digested with trypsin and resuspended in the basic culture medium. The organoid culture samples were collected by centrifugation. RNA was extracted, and DNase enzymes were used to eliminate residual DNA and prevent DNA interference. mRNA was enriched with Oligo(dT)(Thermo Fisher Scientific, Massachusetts, USA). A fragmentation buffer was added to the purified mRNA to produce shorter fragments. The fragmented RNA was then used as a template for reverse transcription with random primers to synthesize the first cDNA strand, followed by the synthesis of the second cDNA strand using the 2nd Strand Marking Buffer and 2nd strand /End Repair Enzyme Mix. After terminal repair, adapters and sequencing joints were added, and the target fragments were recovered through magnetic bead screening. PCR amplification was performed to complete the construction of the whole library. After library construction, Qubit 3.0 (Thermo Fisher Scientific, Massachusetts, USA) was used for preliminary quantification, and the library was diluted to 1 ng/uL. The Agilent 2100 (Agilent Technologies, Palo Alto, USA) instrument was used to detect the insert size of the library. Once the insert size met expectations, the Bio-RAD CFX 96 fluorescent quantitative PCR instrument and the Bio-RAD iQ SYBR Green kit (Bio-Rad, Hercules, USA) were used to perform qPCR to accurately quantify the effective concentration of the library (effective concentration > 10 nM) to ensure library quality. The original data were analyzed, and the genes with altered expression were further investigated. Raw read counts were normalized using the DESeq2 package, which applies size-factor normalization to correct for sequencing depth and library composition. Heatmaps were generated using hierarchical clustering with Euclidean distance and ward.D2 linkage. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Total RNA was obtained from organoid cells using TRIzon Reagent (Beijing ComWin, Beijing, China). According to the manufacturer’s instructions. RNA concentration was determined spectrophotometrically, and its integrity was checked by gel electrophoresis. The reverse transcriptase reactions contained 10 µL of total RNA, 5X Evo M-MLV RT Master Mix (Aikori Biotechnology, Changsha, China), and nuclease-free water. The initial PCR step involved a 30s hold at 95°C, followed by 40 cycles consisting of a 5s denaturation step at 95°C and a 30s annealing/extension step at 63°C. The PCR reactions were run on a 7500 real-time PCR machine (Applied Biosystems, Carlsbad, USA) and analyzed using 7500 System SDS software. All reactions were performed in triplicate and included a negative control lacking cDNA. MTT Assay After trypsin (ANTIBODY and ELISA EXPERTS, Wuhan, China) digestion of the cells in each experimental group during the logarithmic growth phase, the cell suspension was resuspended in the complete medium and counted. The cell density was determined according to the cell growth rate (2000 cells/well in this experiment). Three replicates were performed for each group, and the number of petri dishes was determined according to the experimental design (5 plates in 96-well format were used for 5 days in this experiment). The cells were completely precipitated, and the cell density of each experimental group was observed under a microscope to ensure that the density was roughly the same across groups. The cells were then cultured in a cell incubator. Starting from the second day after plating, 20 μL 5 mg/mL MTT (Sangon Biotech, Shanghai, China) was added to each well 4 h before culture termination, without changing the medium. After 4 h, the culture medium was completely removed, and 100 μL of DMSO was added to dissolve the Formazan particles. The mixture was then oscillated for 2–5 min, and the OD value was detected using an enzyme-labeled instrument at 490/570 nm wavelength. Statistical analysis of the data was conducted afterward. Cell Apoptosis Assay For the cell apoptosis assay, cells were seeded in 6-well plates, and both adherent and floating cells were harvested 72 h after transfection. The cells were stained with Annexin V-FITC and propidium iodide (PI) (Clontech, Palo Alto, USA) for 15 min in the dark at room temperature, followed by flow cytometric analysis. The cell line experiment was performed at least three times to ensure reproducibility. Data analysis was conducted afterward. The gating strategy for quantifying apoptosis involved the use of fluorescently labeled Annexin V and PI. Following the manufacturer’s protocol, a quadrant gate was utilized to distinguish four cellular states: (Q1) Annexin V−/PI+ (necrotic); (Q2) Annexin V+/PI+ (late apoptotic); (Q3) Annexin V−/PI− (viable); and (Q4) Annexin V+/PI− (early apoptotic). Cell Cycle Assay When cells in each experimental group grown in 6 cm dishes reached approximately 80% confluence, trypsin was used to digest the cells. The medium was then resuspended to create a cell suspension, and the cells were collected in 5 mL centrifuge tubes. Each group had three replicates. The samples were centrifuged at 1300 rpm for 5 min, the supernatant was discarded, and the cells were washed with D-Hanks precooled at 4°C (pH=7.2–7.4) and precipitated once. The cells were centrifuged again at 1300 rpm for 5 min and precooled with 75% ethanol at 4°C for 1 h. Afterward, the samples were centrifuged at 1300 rpm for 5 min to remove the fixative, and the cells were washed with D-Hanks and precipitated once more. The cell staining solution was prepared using the following ratios: 40×PI (Meilune)(2 mg/mL), 100×RNase stock solution (10 mg/mL), and 1×D-Hanks at a ratio of 25:10:1000. For cell staining, 1 mL of the staining solution was added to the suspension, and the mixture was incubated at room temperature for 30 min in the dark. Data analysis was conducted afterward. Statistical Analysis All statistical calculations were performed using SPSS 24.0 (SPSS, Inc., Chicago, USA) and GraphPad Prism 9 (GraphPad Software, La Jolla, USA). Each experiment was performed in triplicate. In addition, data are expressed in the form of count or mean±standard deviation. The statistical methods employed in this study included analysis of variance (ANOVA) followed by post hoc tests, and Student’s t-test. ANOVA was utilized to evaluate significant differences in means across three or more groups. Where ANOVA results indicated significance, post hoc tests were conducted to identify specific group differences. For comparisons limited to two groups, either an independent or paired samples t-test was applied, as appropriate to the experimental design. For all calculations, P-values were all two-sided and <0.05 was considered to indicate a statistically significant result. Normality was assessed using the Shapiro–Wilk test, and homogeneity of variances was confirmed by Levene’s test. Parametric tests were applied when both assumptions were met. Results All results described below were obtained from patient-derived organoids established from hormone receptor-positive, HER2-negative breast cancer tissues, unless otherwise specified. Basic Biological Information of Patient-Derived Organoid (PDO) The molecular classification of the hormone receptor and HER2 status for this PDO was ER 95%+/PR 90%+/HER2-. Pathogenic driver mutation information obtained through next-generation sequencing (NGS) in this PDO model included the following: ESR1, D538G, TP53BP1, R1319H, DOT1L, R1170W, AXL, V500M, CCND1, EMSY, FGF19, FGF3, FGF4, FNTA, IKBKB, PAK1 amplifications. Following organoid culture, genomic analysis was performed and compared to the source patient’s genetic profile. The concordance rate for key driver gene mutations was 93.75%. The H&E staining and cell morphology of this PDO are shown in Figure 1. (A and B) Cell morphology of organoid breast cancer cells.(C and D) HE stain of organoid breast cancer cells. (A, C ×20 magnification; B, D ×40 magnification). (E) organoid sensitive to Everolimus. (F) organoid resistant to Everolimus. (A and C) bars 200μm; (B and D) bars 100μm; (E and F) bars 400μm. RNA Sequencing Result Analysis For differential expression analysis, the Benjamini-Hochberg (BH) procedure was applied to control the false discovery rate (FDR). Genes with |log2(fold change)| ≥ 1 and FDR < 0.05 were considered significantly differentially expressed. Compared to the Everolimus-sensitive sample, LRRC32 was significantly upregulated in the Everolimus-resistant sample, with the second-highest fold change of 180.46 (p < 0.001, data not shown). GO enrichment analysis revealed several biological functions, including the negative regulation of cytokine production and the transforming growth factor-beta receptor signaling pathway, among others. The gene with the highest fold change was KLHDC7B, but it was not involved in tumorigenesis pathway and had limited annotation in the GO or KEGG database. LRRC32 was identified as a significantly upregulated gene in the volcano plot, which was further quantified and confirmed in the differential expression analysis (Supplementary materials). LRRC32 Promotes Cell Survival in Hormone Receptor-Positive, HER2-Negative Breast Cancer Cells Based on the MTT assay data, compared with the Everolimus-sensitive group with LRRC32 knockdown, the number of cells in the Everolimus-sensitive group with LRRC32 overexpression was significantly increased at 24 h (P < 0.001), 48 h (P < 0.01), 72 h (P < 0.001), and 96 h (P < 0.01) respectively. Similarly, compared with the Everolimus-resistant group with LRRC32 overexpression, the number of cells in the Everolimus-resistant group with LRRC32 knockdown decreased significantly at 24 h (P < 0.001), 48 h (P < 0.01), 72 h (P < 0.001), and 96 h (P < 0.001) respectively (Figure 2). (A) Manipulation of LRRC32 in Breast cancer organoid cells. (B) Overexpression of LRRC32 promote cell survival in both sensitive and resistant group. Asterisks represent the mean±SD of three biological replicates (**P < 0.01, ***P < 0.001). LRRC32 Affects Cell Cycle Distribution in Hormone Receptor-Positive, HER2-Negative Breast Cancer Cells According to cell cycle analysis results, compared with the Everolimus-sensitive and LRRC32 knockdown group, the proportion of cells in the G1 phase in the Everolimus-sensitive and LRRC32 overexpression group was significantly increased (P < 0.001), while the proportion of cells in the S phase and G2 phase were significantly decreased (P < 0.001 and P < 0.01, respectively). In comparison with the Everolimus-resistant group with LRRC32 overexpression, the proportion of cells in the G1 phase in the Everolimus-resistant group with LRRC32 knockdown was significantly increased (P < 0.001), while the proportions of cells in the S phase (P < 0.01) and G2 phase (P < 0.01) were significantly decreased. The results are shown in Figure 3. (A and B) Overexpression of LRRC32 in Everolimus sensitive cells induced significant increase in the proportion of cells in the G1 phase. (C and D) Knockdown of LRRC32 in Everolimus resistant cells induced significant increase in the proportion of cells in the G1 phase. (E) Summary bar chart demonstrating that modulation of LRRC32 expression induces G1 phase arrest (**P < 0.01, ***P < 0.001). LRRC32 Inhibits Apoptosis in Hormone Receptor-Positive, HER2-Negative Breast Cancer Cells According to the results of the apoptosis assay, the proportion of apoptotic cells in the Everolimus-resistant group of patients with breast cancer was significantly lower than that in the Everolimus-sensitive group (P < 0.001) (Figure 4). (A) Representative image of an Everolimus-sensitive organoid. (B) Representative image of an Everolimus-resistant organoid. (C) Graphical summary confirming the association between Everolimus resistance and reduced apoptosis (***P < 0.001). The proportion of apoptotic cells in the Everolimus-sensitive group with LRRC32 overexpression decreased significantly compared with Everolimus-sensitive with LRRC32 knockdown. Similarly, compared with the Everolimus-resistant group with LRRC32 overexpression, the proportion of apoptotic cells in the Everolimus-resistant group with LRRC32 knockdown was significantly increased (P < 0.001) (Figure 5). LRRC32 inhibits apoptosis to promote cell survival. (A and B) Apoptosis is decreased by LRRC32 overexpression in sensitive cells. (C and D) Apoptosis is increased by LRRC32 knockdown in resistant cells. (E) Summary graph showing the anti-apoptotic correlation of LRRC32 expression (***P < 0.001). Discussion Everolimus, an mTOR inhibitor, received FDA approval in 2012 for use with Exemestane in postmenopausal advanced ER+/HER2- breast cancer patients refractory to prior non-steroidal aromatase inhibitors (Letrozole or Anastrozole).12 However, clinical outcomes with mTOR inhibitors have been suboptimal. Several factors contribute to the limited efficacy of mTOR inhibitors.10,11,13 Studies demonstrate that mTOR signaling in cancer cells promotes myeloid-derived suppressor cell (MDSC) accumulation in breast tumors via granulocyte colony-stimulating factor (G-CSF) induction.14 Inhibiting this pathway or its activators impairs tumor progression, an effect partially reversed by MDSC or G-CSF reconstitution. As key mediators of tumor immune evasion, MDSCs are elevated in breast cancer patients, with abundance increasing during metastatic progression. These cells suppress effector T-cell activity, stimulate anti-inflammatory cytokine secretion (eg, IL-10, TGF-β), induce M2 macrophage polarization, and drive regulatory T-cell (Treg) expansion.15 These observations underscore the complexity of mTOR resistance and the need to identify additional contributing factors. Our study revealed that Everolimus-resistant breast cancer organoids exhibited extensive differential gene expression, with LRRC32 showing the most significant upregulation and strongest correlation with tumor progression. Further functional experiments verified these findings. The overexpression of LRRC32 in Everolimus-sensitive and resistant cells resulted in a significant decrease in apoptosis, promoting cell survival. The overexpression of LRRC32 in Everolimus-sensitive cells induced a significant increase in the proportion of cells in the G1 phase, preventing the cell cycle transition from the G0/G1 to the S phase. In contrast, in the drug-resistant group, LRRC32 overexpression had the opposite effect. These results indicate that modulating the expression of LRRC32 could potentially promote apoptosis and induce cell cycle arrest in tumor cells. The LRRC32 locus is part of a chromosomal region that frequently undergoes changes in human cancer, and specific gene amplification of LRRC32 has been observed in human breast cancer.16 Notably, LRRC32 amplification also increases as hormone sensitivity declines in prostate cancer,17 suggesting a broader role in therapy resistance. GARP, encoded by the LRRC32 gene, is the cell surface docking receptor for latent TGF-β, which is naturally expressed by platelets and regulatory T cells. Regulatory T cells mediate tumor immune escape, particularly in breast cancer metastasis and drug resistance through GARP-dependent activation of TGF-β1. The TRAF3IP3-mediated lysosomal regulation of GARP/TGF-β1 complexes generates active TGF-β1, maintaining immunosuppressive microenvironments and promoting metastasis.18 Targeting this axis is a critical strategy for reversing immunosuppression and enhancing the efficacy of immunotherapy.19 Study has shown that GARP overexpression enhances Foxp3 and Treg activity in immunocompetent breast cancer mice, thereby promoting cancer progression and metastasis. Notably, in orthotopic models of human breast cancer, the administration of GARP-specific monoclonal antibodies limits metastasis.20 Given its role in immune suppression and its association with hormone resistance, LRRC32 may contribute to Everolimus resistance in breast cancer-a possibility that warrants further investigation. In this study, we employed organoid technology for drug sensitivity and functional assays. A major obstacle in drug development is the clinical translation of preclinical findings, where high-fidelity models are critical for success.21 Derived from mechanical/enzymatic digestion of fresh tumor tissues and cultured in specialized matrices, tumor organoids retain parental tumor heterogeneity.22,23 These three-dimensional structures, generated from adult or pluripotent stem cells, recapitulate the spatial architecture of source tissues, enabling long-term stable culture while closely mimicking in vivo microenvironments. Given these advantages, we selected PDOs as the platform for this study to investigate the role of LRRC32 in Everolimus resistance in a clinically relevant setting. There are several limitations to our study. First, the relatively small sample size may limit the statistical power of our analysis; however, the cohort was intentionally focused on a defined tumor subtype (hormone receptor-positive, HER2-negative breast cancer), which minimizes biological heterogeneity and strengthens the internal validity of our findings, rather than weakening their generalizability within this clinically relevant patient population. Second, as a single-center study with a limited number of patients, our findings require validation in larger, independent cohorts to confirm the role of LRRC32 in Everolimus resistance and to assess the generalizability of our results across broader patient populations. Third, a pre-study power analysis was not performed due to the lack of prior effect size estimates from organoid experiments. Fourth, based on the RNA sequencing data, we have not yet experimentally validated the relevant signaling pathways involved in Everolimus resistance. Fifth, the specific proteins mediating the cellular functions of drug resistance remain to be verified through in vitro experiments. Lastly, further in vivo studies are necessary to confirm the effect of LRRC32 on the sensitivity of breast cancer cells to Everolimus in animal models. Conclusion This study demonstrates that LRRC32 mediates resistance to Everolimus in hormone receptor-positive, HER2-negative breast cancer by regulating cell survival and cell-cycle progression. These findings address the primary aim of elucidating key mechanisms underlying mTOR inhibitor resistance in this subtype. Results suggest that LRRC32 targeting could potentiate therapeutic efficacy, providing a novel strategy to overcome Everolimus resistance in hormone receptor-positive, HER2-negative breast cancer. However, in vivo validation and systematic characterization of compensatory resistance pathways require further investigation. Funding Statement This study was supported by grants from the Shandong Provincial Natural Science Foundation of China (ZR2020MH275), and the National Natural Science Foundation of China (81902349). Use of Artificial Intelligence Tools During the preparation of this manuscript the authors used DeepSeek Web Version (https://chat.deepseek.com/) solely to assist with improving the readability and language of the text Specifically it was employed for grammar checking and sentence polishing to enhance clarity. No AI assisted tools were used for the creation or generation of any figures charts or images. All visual content was prepared by the authors using conventional software. After the AI assisted language refinement, the authors thoroughly reviewed edited and verified the entire manuscript to ensure the accuracy and integrity of all scientific content data and conclusions The authors take full responsibility for the final content of the publication. Data Sharing Statement The raw data supporting the findings of this study are available from the corresponding author upon reasonable request. Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University (Ethics approval number SWYX:NO.2022-293) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Consent to Participate Informed consent was obtained from all individual participants included in the study. Consent to Publish The authors affirm that human research participants provided informed consent for publication of the images in figures. Disclosure The authors have no interest in the editors, reviewers, or readers of this journal. The authors have no relevant financial or non-financial interests to disclose. References Associated Data Data Availability Statement The raw data supporting the findings of this study are available from the corresponding author upon reasonable request.